SK Biopharma Adds Preclinical Parkinson’s Candidate in $315M Deal
SK Biopharmaceuticals is expanding its Parkinson’s pipeline with a second preclinical asset from a South Korean partner in a deal worth up to $314.8 million.
SK Biopharmaceuticals has signed a licensing agreement with another South Korean drug developer to add a preclinical Parkinson’s disease therapy to its pipeline. The deal is structured as a biobucks pact, with a total potential value of $314.8 million if all milestones are met.
The candidate is the second preclinical Parkinson’s treatment in SK’s portfolio, signaling a deeper push into early-stage neuroscience research. The agreement follows a typical biobucks structure, where the upfront payment is supplemented by future development and commercial milestones.
This move underscores SK’s continued focus on central nervous system disorders, particularly Parkinson’s disease. By licensing an external asset rather than relying solely on internal discovery, the company is broadening its early-stage options in a competitive therapeutic area.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.